Findings

What do systematic reviews say?

3 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 100%Moderate 0 · 0%High 0 · 0%

Levamisole vs steroids or placebo or both, or no treatment

Clinical relapse · SSNS in children

Levamisole may leads to lower relapse at 6 to 12 months compared with steroids or placebo or both, or no treatment (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.65 [0.48, 0.88]
8 studies · 462 participants
Low

Levamisole vs cyclophosphamide

Relapse · SSNS in children

Levamisole showed no clear difference in relapse: at 6 to 9 months after therapy compared with cyclophosphamide (low certainty).

3 findings from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 1.17 [0.76, 1.81]
2 studies · 97 participants
Low
Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.89 [0.68, 1.16]
1 study · 40 participants
Low
Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.89 [0.73, 1.1]
1 study · 40 participants
Low

Levamisole vs steroids or placebo or both, or no treatment

Relapse during treatment (4 to 12 months) · SSNS in children

Levamisole may leads to lower relapse during treatment (4 to 12 months) compared with steroids or placebo or both, or no treatment (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.52 [0.33, 0.82]
8 studies · 474 participants
Low